Melanotan II: The Evidence Is Present, and It Points the Wrong Way

Melanotan II is approved in no country on earth, and the published literature on it is not thin — it is a two-decade case record of melanoma, eruptive dysplastic naevi, rhabdomyolysis, priapism, renal infarction and posterior reversible encephalopathy syndrome.

That makes it unusual in the libido and sexual wellness peptides category, where the normal problem is missing data. It is also, structurally, one terminal group away from PT-141, a prescription medicine — a distinction of about one dalton that no routine purity test can see.

What does the published literature on melanotan II actually document?

Harm, mostly. The melanotan II literature is not a thin evidence base — it is a two-decade international case literature documenting melanoma and melanoma in situ, oral mucosal melanoma, eruptive dysplastic naevi, rhabdomyolysis with a CPK peak of 17,773 IU/L, priapism, renal infarction and posterior reversible encephalopathy syndrome. These are case reports, so they cannot establish incidence, but the direction of the signal is consistent across multiple countries.

Melanoma and melanoma in situ

Eruptive and dysplastic naevi are the better-documented harm. Hueso-Gabriel et al. 2012 (Actas Dermosifiliográficas, PMID 22425244) is the most fully documented case: a 25-year-old man, phototype II, after four weeks of subcutaneous MT-II, developed "sudden eruption of multiple melanocytic nevi and rapid transformation of existing nevi" — more than 100 naevi, mostly on the back. The ten most atypical were excised: all dysplastic, three with severe dysplasia, plus a pigmented basal cell carcinoma from the shoulder.

Further published cases include Cousen et al. 2009 (Br J Dermatol, PMID 19575725); Schulze et al. 2014 (Eur J Dermatol, PMID 24334249) — eruptive naevi and darkening of pre-existing naevi 24 hours after a single dose; Reid et al. 2013 (Ir Med J, PMID 23914578); Mang et al. 2012 (Der Hautarzt, PMID 23052015); Burian & Burian 2013 (Läkartidningen, PMID 23451671), the first two Swedish cases; and Sivyer 2012 (Dermatol Pract Concept, PMID 23785612) in a teenager with FAMMM syndrome.

Systemic toxicity

The rhabdomyolysis case deserves particular attention. Mass spectrometry confirmed the injected substance was melanotan II — this was not a contaminated or mislabelled product. The molecule itself did it, at a dose the user chose because dosing guidance for an unapproved drug does not exist.

On what this literature is and is not. These are case reports. They establish that these events happened in people using melanotan II; they cannot establish incidence, and melanoma has a long latency with sun exposure and tanning-bed use as confounders in most of these patients. A structured review by Brennan, Wells and Van Hout (Performance Enhancement and Health, 2014) catalogued the harms; it is a narrative review, not a systematic one, and there is no systematic review of melanotan II adverse effects in existence — do not let anyone tell you otherwise in either direction. What can be said is that the signal is consistent, spans multiple countries and two decades, and that FDA independently reached the same list.

Has any trial shown melanotan II works for tanning?

No completed randomised controlled trial of melanotan II for tanning exists. ClinicalTrials.gov returns one record for "melanotan" — NCT07437560, a phase 2 study of MT-II as an adjunct to narrowband UVB phototherapy for repigmentation in stable non-segmental vitiligo, sponsored by Hudson Biotech, estimated enrolment 60, currently recruiting, no results. The only other human material is small early-phase work from the University of Arizona in the 1990s.

That early work is Dorr et al. 1996 (Life Sciences, PMID 8637402), a pilot phase 1 study, and Wessells et al. 2000 (Int J Impot Res, PMID 11035391) on erection and sexual motivation. Those two studies are what launched the compound onto the grey market.

They are not an evidence base for chronic self-administration for cosmetic tanning. A pilot phase 1 study establishes tolerability signals in a handful of supervised subjects over a short window; it says nothing about what happens to a fair-skinned person injecting the same molecule for years. The gap between what those papers tested and what the market does with them is the whole problem.

What have national regulators said about melanotan II?

Five agencies have acted on melanotan II, in unusually direct language. Ireland's HPRA stated on 10 August 2023 that it is "not authorised by the HPRA or any medicines regulator to treat any condition" and removed more than 500 listings in a year. Australia's TGA issued 27 infringement notices totalling $101,412 in May 2026. The MHRA, Denmark's Lægemiddelstyrelsen and FDA have all published equivalent findings.

Ireland — HPRA, 10 August 2023: "Melanotan 2 is not authorised by the HPRA or any medicines regulator to treat any condition." The notice names the risks as "development of new moles, darkening of existing moles and freckles, potential loss of vision, muscle tremors, stroke and anaphylaxis," and advises users to "stop immediately." The HPRA removed more than 500 social media and e-commerce listings between July 2022 and June 2023.

Australia — TGA, 21 May 2026: 27 infringement notices totalling $101,412 issued to a New South Wales individual for alleged unlawful supply. TGA's statement: "There are currently no products containing Melanotan II on the Australian Register of Therapeutic Goods or approved for supply in Australia."

United Kingdom — MHRA, FOI response 24/274, 17 April 2024: "Products containing Melanotan II are classified as medicines if they are injectable or pens"; "the sale, supply and advertising of unauthorised medicines is not permitted." The MHRA received 16 UK Yellow Card adverse drug reaction reports between 2012 and 2022 and states it has "repeatedly taken action to remove Melanotan products from the market for over 10 years."

Denmark — Lægemiddelstyrelsen, 20 June 2011, restating a 2008 alert: the agency warns against the product "because the effect is not documented, and because studies of possible side effects are lacking," describing it as approved neither in Denmark, Europe, nor the USA.

United States — FDA, Notice of Opportunity for Hearing, 5 August 2016: melanotan II "constituted a new drug under the FDCA that could not be introduced or delivered for introduction into interstate commerce without an FDA approved application." The action followed a seller who continued shipping after an August 2007 warning letter, made therapeutic claims about reducing skin cancer risk and curing rosacea, and falsely advertised the product as "100% U.S. made" while importing from China. FDA's note on export: "unapproved new drugs do not qualify for export."

Is melanotan II on FDA's Category 2 list?

Not as of the page current 22 April 2026. Melanotan II moved to a separate table headed "Bulk drug substances nominated but withdrawn," which is a procedural event rather than a safety clearance. FDA's evaluation language is retained on that page and is far stronger than the list placement: it names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism as serious adverse events in published case reports.

The compound is widely described as sitting on FDA's Category 2 list of bulk substances that may present significant safety risks. As of the page current 22 April 2026, it is not.

The active Category 2 list contains fourteen substances: cesium chloride, chloral hydrate, diethylstilbestrol, domperidone, edetate disodium, germanium sesquioxide, GHRP-2, GHRP-6, ibutamoren mesylate, ipamorelin acetate, kisspeptin-10, neomycin sulfate, quinacrine hydrochloride and tranilast. Melanotan II is not among them. It appears instead in the withdrawn-nomination table, alongside AOD-9604, BPC-157, LL-37, CJC-1295, DSIP, epitalon, GHK-Cu, KPV, PEG-MGF, MOTS-c, selank acetate, semax, thymosin α1 and thymosin beta-4 fragment.

FDA's evaluation language for melanotan II is retained on that page, and it is worth quoting in full because it is far stronger than the list placement:

"Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism."

That is FDA naming four specific serious harms. Nothing about the move to the withdrawn-nomination table changes it — the nomination was withdrawn by the nominator, which is a procedural event, not a safety clearance. Melanotan II is not on the 503A bulks list either, has no USP monograph and is not a component of any approved drug. It cannot be legally compounded, and it remains an unapproved new drug.

WADA: melanotan II is not named on the 2026 Prohibited List, but the S0 catch-all captures "any pharmacological substance... with no current approval by any governmental regulatory health authority for human therapeutic use." Melanotan II holds no approval anywhere, so S0 applies. Prohibited at all times. See our FDA peptide regulation timeline.

What is melanotan II, and why does non-selectivity matter?

Melanotan II is a cyclic heptapeptide analogue of α-MSH — Ac-Nle⁴-c[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂, CAS 121062-08-6, 1,024.18 g/mol — and it is a non-selective melanocortin agonist. It activates MC1R for pigmentation, MC3R and MC4R for appetite, sexual function and autonomic effects, and MC5R. The tan, the libido effect, the nausea and the priapism are one drug hitting different receptors. There is no dose that produces one without risking the others.

Structurally it is built from the α-MSH message core, with norleucine at position 4, D-phenylalanine at position 7, and an Asp5→Lys10 lactam bridge. The C-terminus is a lysine amide, and that single detail carries the whole identity story.

Non-selectivity is what makes the harm list coherent. Priapism is not an idiosyncratic reaction to a tanning drug; it is MC4R activation. Nausea is the same. The case literature reads like a scattered collection of unrelated events only if you assume the compound is a pigmentation agent. It is not — it is a melanocortin agonist with no receptor selectivity, and the pigmentation is one of four things it does at once.

Why is melanotan II unapproved when a near-identical molecule is a prescription drug?

Because approval attaches to a molecule, not a backbone. Melanotan II differs from bremelanotide only at the C-terminus — a lysine amide (–NH₂) against a free acid (–OH) — about 1 dalton on 1,024.18 versus 1,025.2, under 0.1%. Bremelanotide holds FDA approval as VYLEESI; melanotan II is approved in no country on earth. The gap in legal standing is total, and the gap in mass is under one part in a thousand.

The consequence for a buyer runs in one direction only. Someone ordering bremelanotide has to worry about receiving melanotan II; someone ordering melanotan II is not being defrauded if the vial is correct. Either way, a separation of under 0.1% is beyond what HPLC purity testing or nominal-mass mass spectrometry can resolve, and high-resolution MS or MS/MS fragmentation is required.

Two published analytical studies exist on exactly this problem. Mestria et al. (Drug Testing and Analysis, 2021) characterised black-market melanotan II and bremelanotide by LC-HRMS, and Breindahl et al. (Drug Testing and Analysis, 2015) identified and characterised melanotan II products sold illegally online. Their existence tells you the market has an identity problem serious enough for forensic chemists to study. See mass spectrometry for peptides.

Which melanotan II claims survive the evidence?

Exactly one. Of nine claims assessed, only one made in melanotan II's favour survives — it does produce tanning, because MC1R pharmacology is real and pigmentation occurs. The rest fail: approved nowhere, no completed efficacy trial, FDA naming four serious harms, and no way to tell it from PT-141 by purity testing. The claims that do hold up beyond tanning are the ones against it.

What does the approved melanocortin agonist require that melanotan II does not?

Afamelanotide (Scenesse) requires a physician. Approved under NDA 210797 on 8 October 2019 for erythropoietic protoporphyria, it is a 16 mg subcutaneous implant inserted by a health care professional trained by the manufacturer, above the anterior supra-iliac crest, every two months, with twice-yearly full-body skin examinations recommended and an eight-year minimum prospective registry focused on skin cancer. Melanotan II is self-injected at home with none of that.

Four things follow from that table. Afamelanotide is a different molecule — 1,647 Da linear versus 1,024 Da cyclic — not a formulation variant. It is approved for a rare metabolic photodermatosis, not cosmetic tanning, and the benefit measured was pain-free light exposure. It is implanted by a trained clinician, not self-injected. And even with all that control, FDA required twice-yearly skin examinations and an eight-year skin cancer registry.

That registry requirement is the regulator's own assessment of what a melanocortin agonist does to pigmented lesions over time. It applies to the version with a physician, a defined dose and a rare-disease indication. None of it reaches anyone injecting melanotan II at home.

What does the platform data show for melanotan II?

The Purity Index records melanotan II at 99.62% across 251 independent tests from laboratories including ILS, MZ Biolabs, Kovera, Janoshik and Freedom Diagnostics, across 226 verified shops (verified August 2026). Quantity variance runs −7.3% to +16%, and endotoxin results are mostly absent. Price data shows 69 shops in stock at a median of $3.80 per milligram, lowest $1.50/mg on a 10 mg vial (verified 10 August 2026).

Melanotan II price data puts the highest listing at $9.00/mg (verified 10 August 2026), from 173 known shops. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

For scale, those 251 tests sit inside a platform total of 11,852 independent lab tests across 118 peptides and 530 shops, with 1,283 community reviews (verified August 2026). The volume of testing on this compound is not the problem. What those tests can and cannot establish is, and that is the subject of the next section.

What can a certificate of analysis confirm about melanotan II?

Less than the risk requires. A certificate can confirm homogeneity and, with high-resolution MS or MS/MS, distinguish melanotan II at 1,024.18 from PT-141 at 1,025.2 — but purity is not the risk here. The harms in the case literature came from correctly identified, correctly manufactured melanotan II; mass spectrometry confirmed the injected material in the rhabdomyolysis case. A 99.62% pure vial delivers exactly the pharmacology that produced those reports.

This is the one compound on this platform where a high purity score should provide no reassurance at all, because the molecule is the problem.

Compare vendors on the melanotan II compound page, see where to buy melanotan II for identity checks, melanotan 1 versus melanotan 2 for the analogue comparison, and how to read peptide lab results for reading a certificate line by line.

The trial that would settle this

The trial that would settle melanotan II has to be randomised, controlled and prospective, because the entire safety literature is case reports. Its primary endpoint would be dermatoscopic naevus counts and atypia, since eruptive naevi is the most consistently reported harm; it would run for years with a melanoma registry attached, enrol Fitzpatrick phototypes I and II, and map every mole before the first dose. It will not be run.

There is no sponsor for a cosmetic indication in a compound already prosecuted as an unapproved new drug in multiple jurisdictions. That absence is permanent, and it should be factored into any decision about the compound rather than treated as a temporary gap that better evidence will one day close.

Frequently Asked Questions

Is melanotan II legal?

It is approved in no country. Regulators in Ireland, the UK, Australia, Denmark and the United States have all stated it is unauthorised, and several have taken enforcement action — Australia's TGA issued 27 infringement notices totalling $101,412 in May 2026 for unlawful supply.

Is melanotan II on FDA's Category 2 list?

Not as of the page current 22 April 2026 — it moved to a table of nominations withdrawn by the nominator. That is procedural. FDA's evaluation language remains published and names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism as documented serious adverse events.

Does melanotan II cause melanoma?

Multiple case reports document melanoma and melanoma in situ in users, including oral mucosal melanoma after nasal spray use and five simultaneous primary melanomas in situ in one patient. Case reports cannot establish incidence, and tanning-bed use and sun exposure confound most of them. What is much better documented is eruptive and dysplastic naevi — one patient developed more than 100 new moles after four weeks, with severe dysplasia in three of ten excised.

Is melanotan II the same as PT-141?

Nearly. They share the same backbone and lactam bridge and differ only at the C-terminus — an amide versus an acid, about 1 dalton on 1,024. PT-141 is FDA-approved as Vyleesi; melanotan II is approved nowhere. Routine HPLC and nominal-mass MS cannot tell them apart.

Isn't there an approved version of melanotan II?

Afamelanotide (Scenesse) is an approved melanocortin agonist, but it is a different molecule — a linear 13-mer at 1,647 Da — approved for erythropoietic protoporphyria, administered as a physician-inserted implant every two months, with recommended twice-yearly full-body skin examinations and an eight-year FDA-mandated skin cancer registry.

Is melanotan II banned in sport?

Yes. It is not named on the WADA 2026 list, but the S0 catch-all prohibits substances with no current approval from any governmental health authority. Melanotan II has none. Prohibited at all times.

Where melanotan II sits

Melanotan II is the compound where the evidence is present and points the wrong way. Most articles on this platform end by noting that evidence for a compound is absent; here there is a two-decade international case literature documenting melanoma, eruptive dysplastic naevi, rhabdomyolysis with a CPK of 17,773, priapism, renal infarction and PRES, five national regulators on record, and no completed efficacy trial for tanning.

The one recruiting study is for a vitiligo indication with no results yet. FDA's own evaluation names four of those harms in a single sentence, reached independently of the dermatology case literature that reports them.

And the closest legitimate comparator — the approved melanocortin agonist for a rare photosensitivity disorder — is delivered by implant, by a trained clinician, with twice-yearly skin checks and an eight-year cancer registry attached. The gap between those two administration models is not a matter of convenience or regulatory friction. It is what a regulator concluded was necessary to use this class of drug safely, in a patient who needs it.

Browse the libido and sexual wellness peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.